NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IMNN

Imunon Inc

Jul 14 • 04:00PM ET

0.5200

Dollar change -0.0851
Percentage change -14.06	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX DVAX INO VXRT PDSB AVIR ADMA CLOV

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.41	Insider Own	12.56%	Shs Outstand	20.32M	Perf Week	-28.77%
Market Cap	10.57M	Forward P/E	-	EPS next Y	-0.42	Insider Trans	0.99%	Shs Float	17.77M	Perf Month	-68.67%
Enterprise Value	8.71M	PEG	-	EPS next Q	-0.32	Inst Own	7.94%	Short Float	6.13%	Perf Quarter	-39.53%
Income	-17.79M	P/S	-	EPS this Y	42.44%	Inst Trans	1.03%	Short Ratio	0.09	Perf Half Y	-42.83%
Sales	0.00M	P/B	16.82	EPS next Y	54.60%	ROA	-167.96%	Short Interest	1.09M	Perf YTD	-45.26%
Book/sh	0.03	P/C	3.68	EPS next 5Y	37.97%	ROE	-397.54%	52W High	3.65 -85.75%	Perf Year	-61.19%
Cash/sh	0.14	P/FCF	-	EPS past 3/5Y	69.57% 32.54%	ROIC	-1670.41%	52W Low	0.37 40.54%	Perf 3Y	-76.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.70% 10.71%	Perf 5Y	-99.09%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	30.50%	Oper. Margin	-	ATR (14)	0.16	Perf 10Y	-99.89%
Dividend Ex-Date	-	Quick Ratio	0.88	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	33.08	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	0.88	EPS Q/Q	46.26%	SMA20	-38.89%	Beta	2.19	Target Price	11.25
Payout	-	Debt/Eq	2.24	Sales Q/Q	-	SMA50	-50.45%	Rel Volume	0.20	Prev Close	0.61
Employees	25	LT Debt/Eq	1.36	Earnings	May 12 BMO	SMA200	-44.74%	Avg Volume	11.54M	Price	0.52
IPO	Apr 04, 1994	Option/Short	No / Yes	EPS/Sales Surpr.	20.00% -	Trades		Volume	2,334,153	Change	-14.06%

Jun-30-25 08:00AM	IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq's Listing Requirement, Anticipates Additional Compliance Period (GlobeNewswire) +8.11%
Jun-18-25 08:05AM	IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 (GlobeNewswire) -11.50%
Jun-17-25 08:05AM	IMUNON Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development (GlobeNewswire)
Jun-13-25 08:35AM	Life Sciences Investor Forum: Now Available for Online Viewing (GlobeNewswire) -11.73%
Jun-10-25 02:38PM	Life Sciences Investor Forum Agenda Announced for June 11th-12th (GlobeNewswire) +21.80%
08:00AM	Loading…
Jun-05-25 08:00AM	IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th (GlobeNewswire) -17.65%
Jun-04-25 07:41AM	ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer (Clinical Trials Arena) -10.99%
Jun-03-25 08:05AM	IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study (GlobeNewswire) -23.90%
Jun-02-25 08:05AM	IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS (GlobeNewswire)
May-28-25 11:55PM	Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More (Insider Monkey) -33.04% +30.92%
05:16PM	IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
May-27-25 08:20AM	Imunon announces up to $9.75M private placement priced at-the-market (TipRanks) +95.69%
08:05AM	IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 (GlobeNewswire)
May-23-25 06:59PM	IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +179.18%
08:05AM	IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire)
05:20PM	Loading…
May-22-25 05:20PM	IMUNON Announces Withdrawal of Form S-1 Registration Statement (GlobeNewswire)
May-15-25 08:05AM	IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 (GlobeNewswire) -8.37%
May-13-25 03:07AM	Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
01:59AM	Q1 2025 Imunon Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 08:00AM	IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-08-25 08:05AM	IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire)
May-06-25 08:05AM	IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology (GlobeNewswire)
May-05-25 08:00AM	IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 (GlobeNewswire)
Apr-21-25 08:05AM	IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting (GlobeNewswire)
Mar-25-25 06:48AM	FDA aligns with Imunons Phase III trial protocol for ovarian cancer treatment (Clinical Trials Arena) -6.11%
Mar-24-25 08:00AM	IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer (GlobeNewswire) +12.11%
Feb-28-25 04:29AM	Q4 2024 Imunon Inc Earnings Call (Thomson Reuters StreetEvents) +9.96%
02:28AM	Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges (GuruFocus.com)
Feb-27-25 08:05AM	IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study (GlobeNewswire)
07:36AM	Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial (Clinical Trials Arena)
08:05AM	Loading…
Feb-26-25 08:05AM	IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19 (GlobeNewswire)
Feb-20-25 08:30AM	IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025 (GlobeNewswire)
Feb-19-25 08:05AM	IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer (GlobeNewswire)
Feb-10-25 08:05AM	IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Dec-19-24 08:05AM	IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer (GlobeNewswire)
Dec-10-24 08:05AM	IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 (GlobeNewswire)
Nov-25-24 08:05AM	IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer (GlobeNewswire)
Nov-08-24 02:23AM	Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... (GuruFocus.com)
Nov-07-24 10:00AM	IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting (GlobeNewswire) -12.34%
08:05AM	IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Oct-31-24 08:30AM	IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 (GlobeNewswire)
Oct-30-24 09:05AM	IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting (GlobeNewswire)
Oct-08-24 08:45AM	Imunon reports inducement grant under NASDAQ listing rule (TipRanks)
Oct-07-24 08:05AM	IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
Sep-09-24 04:06PM	UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)
08:30AM	IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)
Aug-28-24 08:30AM	IMUNON to Host R&D Day on September 18th (GlobeNewswire)
Aug-14-24 08:00AM	IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) -11.44%
Aug-07-24 05:04PM	IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024 (GlobeNewswire) -7.76%
Jul-31-24 11:54AM	Imunons shares soar after IL-12 therapy success in Phase II trial (Pharmaceutical Technology) -59.34%
08:00AM	IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Jul-30-24 08:00AM	IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 (GlobeNewswire) +178.99%
Jul-29-24 04:05PM	IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow (GlobeNewswire)
Jun-24-24 08:30AM	IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer (GlobeNewswire)
Jun-05-24 08:30AM	First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial (GlobeNewswire)
May-15-24 08:30AM	Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-14-24 06:08AM	Q1 2024 Imunon Inc Earnings Call (Thomson Reuters StreetEvents) -9.12%
03:02AM	Imunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-13-24 12:52PM	IMNN Stock Earnings: Imunon Beats EPS for Q1 2024 (InvestorPlace) +7.25%
09:00AM	IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study (GlobeNewswire)
08:00AM	IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 08:00AM	IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO (GlobeNewswire) +17.19%
May-06-24 11:00AM	IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024 (GlobeNewswire)
Apr-18-24 08:30AM	IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 (GlobeNewswire)
Apr-11-24 08:00AM	IMUNON Reports Compliance with Nasdaq Listing Requirements (GlobeNewswire) +6.21%
Apr-01-24 07:08PM	Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript (Insider Monkey) +17.68% -9.33%
Mar-28-24 12:52PM	IMNN Stock Earnings: Imunon Beats EPS for Q4 2023 (InvestorPlace) +17.14%
08:00AM	IMUNON Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-24 08:30AM	IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses (GlobeNewswire)
Mar-21-24 05:00PM	IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 (GlobeNewswire) +6.42% +6.01%
Mar-13-24 08:00AM	IMUNON Files IND Application to Begin Human Testing of IMNN-101 (GlobeNewswire) -6.34%
Mar-12-24 05:00PM	IMUNON Announces Leadership Change (GlobeNewswire) -5.98%
Feb-29-24 08:30AM	Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 (GlobeNewswire) +16.33%
Feb-27-24 08:30AM	Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer (GlobeNewswire) +16.37%
Feb-22-24 08:00AM	IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine (GlobeNewswire) +5.23%
Dec-11-23 08:30AM	IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 06:45PM	Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 09:00AM	IMUNON's VP of R&D to Present at the Vaccines Summit-2023 (GlobeNewswire)
08:00AM	IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-23 08:30AM	IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023 (GlobeNewswire)
Oct-23-23 08:30AM	IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress (GlobeNewswire) +7.53%
Oct-19-23 08:30AM	IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations (GlobeNewswire)
Oct-18-23 08:30AM	IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer (GlobeNewswire)
Oct-06-23 08:30AM	IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board (GlobeNewswire)
Sep-28-23 08:30AM	IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer (GlobeNewswire) -6.86%
Sep-26-23 08:30AM	IMUNON Releases Enterprise Video Highlighting the Companys Mission, Vision, Values, Breakthroughs and Technologies (GlobeNewswire)
Sep-18-23 07:08AM	IMNN: R&D Day Highlights Company Pipeline (Zacks)
Sep-13-23 08:30AM	IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET (GlobeNewswire)
Sep-07-23 04:30PM	IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET (GlobeNewswire) -5.74%
Sep-05-23 08:30AM	IMUNON to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-25-23 12:09PM	Imunon Inc's Rocky Road Ahead: Unraveling the Factors Limiting Growth (GuruFocus.com) +9.01%
11:38AM	Is Imunon (IMNN) Modestly Overvalued? A Comprehensive Valuation Analysis (GuruFocus.com)
Aug-24-23 04:05PM	IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus (GlobeNewswire)
Aug-22-23 09:25AM	IMNN: Manuscript Preprint on COVID-19 DNA Vaccine Published (Zacks Small Cap Research)
Aug-15-23 06:11AM	Imunon, Inc. (NASDAQ:IMNN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-14-23 08:30AM	IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla (GlobeNewswire)
Aug-11-23 04:16AM	Q2 2023 Imunon Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 08:00AM	IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-23 08:30AM	Preclinical Data Showing Strong Immunogenicity and Protection with IMUNONs PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv (GlobeNewswire)
Aug-03-23 08:30AM	IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023 (GlobeNewswire)

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Braun Donald P	Director	Aug 20 '24	Buy	1.18	25,000	29,480	25,597	Jan 28 04:18 PM
Lindborg Stacy	President and CEO	Aug 15 '24	Buy	0.98	25,000	24,500	264,166	Aug 16 08:03 AM
Tardugno Michael H	Executive Chairman of Board	Aug 15 '24	Buy	1.03	25,000	25,750	353,346	Aug 16 08:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMNN

Imunon Inc

Upgrade your FINVIZ experience